Results 1 to 10 of about 150,706 (165)

Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models

Frontiers in Immunology, 2023
Solid organ transplant represents a potentially lifesaving procedure for patients suffering from end-stage heart, lung, liver, and kidney failure.
Ramzi Abboud, Sena Kim, Karl Staser, Reyka G. Jayasinghe, Sora Lim, Parmeshwar Amatya, C. Corbin Frye, Benjamin Kopecky, Julie Ritchey, Feng Gao, Kory Lavine, Daniel Kreisel, John F. DiPersio, Jaebok Choi   +13 more
doaj   +1 more source

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition

Haematologica, 2020
MCL-1 and BCL-2 are both frequently overexpressed in acute myeloid leukemia (AML) and critical for the survival of AML cells and AML stem cells. MCL-1 is a key factor in venetoclax resistance.
Bing Z. Carter, Po Yee Mak, Wenjing Tao, Marc Warmoes, Philip L. Lorenzi, Duncan Mak, Vivian Ruvolo, Lin Tan, Justin Cidado, Lisa Drew, Michael Andreeff   +10 more
doaj   +1 more source

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

Scientific Reports, 2021
Peposertib (M3814) is a potent and selective DNA-PK inhibitor in early clinical development. It effectively blocks non-homologous end-joining repair of DNA double-strand breaks (DSB) and strongly potentiates the antitumor effect of ionizing radiation (IR)
Eric Haines, Yuki Nishida, Michael I. Carr, Rafael Heinz Montoya, Lauren B. Ostermann, Weiguo Zhang, Frank T. Zenke, Andree Blaukat, Michael Andreeff, Lyubomir T. Vassilev   +9 more
doaj   +1 more source

Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival

Haematologica, 2018
Mesenchymal stromal cells (MSC) support acute myeloid leukemia (AML) cell survival in the bone marrow (BM) microenvironment. Protein expression profiles of AML-derived MSC are unknown.
Steven M. Kornblau, Peter P. Ruvolo, Rui-Yu Wang, V. Lokesh Battula, Elizabeth J. Shpall, Vivian R. Ruvolo, Teresa McQueen, YiHua Qui, Zhihong Zeng, Sherry Pierce, Rodrigo Jacamo, Suk-Young Yoo, Phuong M. Le, Jeffrey Sun, Numsen Hail, Marina Konopleva, Michael Andreeff   +16 more
doaj   +1 more source

Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model

Haematologica, 2020
Although highly effective, BCR-ABL1 tyrosine kinase inhibitors do not target chronic myeloid leukemia (CML) stem cells. Most patients relapse upon tyrosine kinase inhibitor therapy cessation.
Bing Z. Carter, Po Yee Mak, Hong Mu, Xiangmeng Wang, Wenjing Tao, Duncan H. Mak, Elisha J. Dettman, Michael Cardone, Oleg Zernovak, Takahiko Seki, Michael Andreeff   +10 more
doaj   +1 more source

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models

Frontiers in Immunology, 2022
Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with recurrent/refractory acute myeloid leukemia (AML).
Hong Mu-Mosley, Lauren Ostermann, Muharrem Muftuoglu, Abishek Vaidya, Challice L. Bonifant, Mireya Paulina Velasquez, Stephen Gottschalk, Michael Andreeff   +7 more
doaj   +1 more source

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

Haematologica, 2018
Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clinical efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K ...
Weiguo Zhang, Charlie Ly, Jo Ishizawa, Hong Mu, Vivian Ruvolo, Sharon Shacham, Naval Daver, Michael Andreeff   +7 more
doaj   +1 more source

Superoxide Dismutase and Vitamin E Levels in Serum as Indicators in Patients with Acute and Chronic Leukemia [PDF]

Journal of Applied Sciences and Nanotechnology, 2022
Oxidative stress has been linked to the development of a variety of malignancies, including leukemia. Furthermore, the incidence of leukemia increases with age due to an increase in the number of free radicals reacting with age and a lower ability of the
Reem Al-Qaisi, Abdulnasser Al-Gebori, Mohammed Alosami   +2 more
doaj   +1 more source

The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients

Cells, 2023
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Common causes include gram-negative and gram-positive bacteria as well as fungi.
Øystein Bruserud, Knut Anders Mosevoll, Øyvind Bruserud, Håkon Reikvam, Øystein Wendelbo   +4 more
doaj   +1 more source

The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia

Hemato, 2021
About 10% of newly diagnosed and 20–30% of therapy-related acute myeloid leukemia (AML) harbors a TP53 mutation (mTP53-AML). Unfortunately, this biological subset predicts one of the worst prognoses among patients with AML, specifically a median overall ...
Rory M. Shallis, Maximilian Stahl, Jan Philipp Bewersdorf, Amer M. Zeidan   +3 more
doaj   +1 more source